Stay updated with breaking news from Morpheus Lung. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Milestone payment triggered by dosing of the first patient in camonsertib-based arm in Roche’s Phase 2 TAPISTRY platform clinical trial Repare is eligible to receive up to $1.2 billion in...
Repare Therapeutics Inc. , a leading clinical-stage precision oncology company, today provided a corporate update and highlighted key milestones anticipated in 2024. “We significantly advanced...
Presented initial camonsertib-PARPi combination Phase 1/2 clinical data at AACR 2023 demonstrating durable clinical benefit across tumor types, genomic alterations, PARPi choice or platinum resistanceRoche has included a camonsertib-based arm in its Phase 2 TAPISTRY study and its Phase 1/2 Morpheus Lung study of mul...